Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Breast Cancer Therapeutics Market Size to Reach USD 95.14 Billion at a CAGR of 9.20% from 2035 – SNS Insider

globenewswire.com
PFE Pfizer Inc. is mentioned as a key company in the breast cancer therapeutics market, which is projected to grow significantly. The article highlights advancements in therapies that Pfizer is likely involved in, but does not provide specific performance details for the company. LLY Eli Lilly and Company is listed as a key player in the growing breast cancer therapeutics market. The article discusses trends like targeted therapies and ADCs, areas where Lilly is active, but offers no specific sentiment on their performance. MRK Merck & Co., Inc. is identified as a key company in the breast cancer therapeutics market, which is expected to experience substantial growth. The article mentions immunotherapy as a growing segment, an area where Merck has significant involvement, but provides no direct sentiment on the company. GILD Gilead Sciences, Inc. is named as a key participant in the expanding breast cancer therapeutics market. The article touches upon advancements in targeted therapies and immunotherapy, fields relevant to Gilead's focus, but does not offer specific sentiment for the company. ABBV AbbVie Inc. is listed among the key companies in the breast cancer therapeutics market, which is projected for significant growth. The article discusses various therapeutic approaches relevant to AbbVie's business, but provides no specific sentiment on the company's performance. BMY Bristol-Myers Squibb Company is mentioned as a key player in the breast cancer therapeutics market, which is expected to grow substantially. The article highlights immunotherapy as a key growth area, relevant to BMS's portfolio, but offers no direct sentiment on the company. AMGN Amgen Inc. is identified as a key company in the breast cancer therapeutics market, which is poised for significant growth. The article discusses trends like targeted therapies and ADCs, areas where Amgen is active, but provides no specific sentiment on the company's performance. PBYI Puma Biotechnology, Inc. is named as a key company in the breast cancer therapeutics market, which is projected to grow. The article mentions targeted therapies and ADCs, which are relevant to Puma's focus, but does not offer specific sentiment for the company. GSK GlaxoSmithKline plc is listed as a key company in the breast cancer therapeutics market, which is expected to grow significantly. The article discusses advancements in immunotherapy and ADCs, areas relevant to GSK's pipeline, but provides no specific sentiment for the company. TEVA Teva Pharmaceutical Industries Ltd. is mentioned as a key company in the breast cancer therapeutics market, which is projected for substantial growth. The article discusses various therapeutic approaches, but offers no specific sentiment on Teva's performance or market position. EXEL Exelixis, Inc. is identified as a key company in the breast cancer therapeutics market, which is expected to grow. The article mentions targeted therapies and precision medicines, areas relevant to Exelixis, but provides no specific sentiment on the company.

Breast Cancer Therapeutics Market Size to Reach USD 95.14 Billion at a CAGR of 9.20% from 2035 – SNS Insider Austin, United States, Aug. 28, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, the Breast Cancer Therapeutics Market was valued at USD 39.46 billion in 2025 and is projected to reach USD 95.14 billion by 2035, growing at a CAGR of 9.20% from 2026 to 2035. Growth of the market is supported by the growing incidence of breast cancer, improved access to screening and treatment facilities, and further adoption of novel therapies such as targeted therapy, CDK4/6 inhibitors, immunotherapy, and ADCs.

Therapeutic approaches are becoming more and more based on tumor biology and biomarker profile. The increasing utilization of biomarkers, such as HER2 and hormone receptors is facilitating the appropriate matching of drugs to patients, whereas oral and subcutaneous delivery methods are making treatment more flexible.

Download the Breast Cancer Therapeutics Market Sample Report: https://www.snsinsider.com/sample-request/2943

Breast Cancer Therapeutics Market Highlights

Breast Cancer Therapeutics Market Growth Drivers and Treatment Trends

The breast cancer therapeutics market is moving from conventional therapy treatments to personalized cancer therapy based on biomarkers. The largest segment of treatment is still targeted therapies due to wide use of HER2-targeting drugs, endocrine therapy combinations, CDK4/6 inhibitors, and other precision medicines.

Antibody-drug conjugates are increasing the number of treatment choices in patients with HER2-positive cancers, HER2-low cancers, and other forms of breast cancer using targeted drug delivery and cytotoxic action.

Immunotherapy is becoming increasingly important, especially for the treatment of triple-negative breast cancer using checkpoint inhibitors and combination therapies. At the same time, pharmaceutical companies are developing next-generation ADCs, subcutaneous treatments, and AI technologies to develop new oncology medicines.

High costs of treatment, toxicity of treatments, regulatory challenges, and high potency required in ADCs are some of the major factors restraining the market.

Regional Breast Cancer Therapeutics Market Outlook

North America accounted for 38.61% of global revenue in 2025, making it the largest regional market. The United States accounted for 84.60% of revenues in North America due to its well-established healthcare infrastructure, robust development of pharma R&D, and quick implementation of novel breast cancer treatments.

The U.S. Breast Cancer Therapeutics Market was valued at USD 12.89 billion in 2025 and is projected to reach USD 31.08 billion by 2035, growing at a CAGR of 9.20%.

The Europe Breast Cancer Therapeutics Market was valued at USD 11.44 billion in 2025 and is forecast to reach USD 26.47 billion by 2035, growing at a CAGR of 8.70%. Germany accounted for approximately 23.80% of European revenue in 2025.

The market in Asia Pacific is expected to have the highest growth rate among all regions. China is expected to contribute to 36.60% of the revenue generated in the Asia Pacific region owing to healthcare infrastructure expansion, increased drug manufacturing capacity, and improved access to cancer care in 2025.

In the Middle East & Africa, Saudi Arabia accounted for approximately 23.60% of regional revenue in 2025. In Latin America, Brazil represented approximately 27.40% of regional revenue.

Buy the Breast Cancer Therapeutics Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/2943

Breast Cancer Therapeutics Market Segment Analysis

By Therapy Type: Targeted Therapy had a market share of 64.85% in 2025 due to HER2 Targeted Therapies and other biomarker-based therapies. The fastest growing therapy type is expected to be Immunotherapy with CAGR of 14.25%, driven by checkpoint inhibitors and combination regimens.

By Cancer Type: Hormone Receptor Positive breast cancer accounted for 66.97% of market revenue in 2025. Triple-Negative breast cancer is forecast to grow at a 12.35% CAGR, supported by increasing adoption of immunotherapies and antibody-drug conjugates.

By Distribution Channel: Hospital Pharmacies held 66.61% share in 2025, reflecting specialist handling and administration requirements for many injectable and infusion-based therapies. Online Pharmacies are projected to grow at an 11.80% CAGR as oral targeted medicines and prescription delivery expand.

By Route of Administration: Oral therapies accounted for 58.60% of market revenue in 2025. Injectable/Subcutaneous therapies are forecast to grow at an 11.62% CAGR as manufacturers develop formulations designed to reduce administration time and treatment-center burden.

Competitive Landscape

Competition in the Breast Cancer Therapeutics Market is increasingly focused on biomarker-defined patient populations, improved efficacy, reduced toxicity, next-generation antibody-drug conjugates, combination regimens, and more convenient administration formats.

Key companies include Roche Holding AG (Genentech), Pfizer Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Merck & Co., Inc., Gilead Sciences, Inc., Daiichi Sankyo Company, Limited, AbbVie Inc., Bristol-Myers Squibb Company, Sanofi S.A., Amgen Inc., Seagen Inc. (Pfizer), Puma Biotechnology, Inc., Eisai Co., Ltd., GlaxoSmithKline plc, Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., and Exelixis, Inc.

Explore the Complete Breast Cancer Therapeutics Market Report: https://www.snsinsider.com/reports/breast-cancer-therapeutics-market-2943